Adaptive Biotechnologies Corporation stock is down -3.73% since 30 days ago. The next earnings date is Feb 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It serves the life sciences research, clinical diagnostics, and drug discovery applications.